Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancerReportar como inadecuado

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Translational Medicine

, 13:150

First Online: 08 May 2015Received: 07 January 2015Accepted: 28 April 2015DOI: 10.1186-s12967-015-0509-x

Cite this article as: Yamamoto, Y., De Velasco, M.A., Kura, Y. et al. J Transl Med 2015 13: 150. doi:10.1186-s12967-015-0509-x


BackgroundDespite recent advances in the treatment for advanced prostate cancer, outcomes remain poor. This lack of efficacy has prompted the development of alternative treatment strategies. In the present study we investigate the effects of the multikinase inhibitor sorafenib in a genetically engineered mouse model of prostate cancer and explore the rational combination with the mTOR inhibitor everolimus.

MethodsConditional prostate specific PTEN-deficient knockout mice were utilized to determine the pharmacodynamic and chemopreventive effects of sorafenib. This mouse model was also used to examine the therapeutic efficacy of sorafenib alone or in combination with everolimus. Preclinical efficacy was assessed by comparing the reduction of tumor burden, proliferation, angiogenesis and the induction of apoptosis. Molecular responses were assessed by immunohistochemical, TUNEL and western blot assays.

ResultsPharmacodynamic analysis revealed that a single dose of sorafenib decreased activation of the PI3K-AKT-mTOR signaling axis at doses of 30–60 mg-kg, but activated JAK-STAT3 signaling. Levels of cleaved casapase-3 increased in a dose dependent manner. Chemoprevention studies showed that chronic sorafenib administration was capable of inhibiting tumor progression through the reduction of cancer cell proliferation, angiogenesis and the induction of apoptosis. In intervention models of established castration-naïve and castration-resistant prostate cancer, treatment with sorafenib provided modest but statistically insignificant reduction in tumor burden. However, sorafenib significantly inhibited cancer cell proliferation and MVD but had minimal effects on the induction of apoptosis. Interestingly, the administration of sorafenib increased the expression levels of the androgen receptor, p-GSK3β and p-ERK1-2 in castration-resistant prostate cancers. In both intervention models, combination therapy demonstrated a clear tendency of enhanced antitumor effects over monotherapy. Notably, the treatment combination of sorafenib and everolimus overcame therapeutic escape from single agent therapy in castration-resistant prostate cancers.

ConclusionsIn summary, we provide insights into the molecular responses of sorafenib therapy in a clinically relevant model of prostate cancer and present preclinical evidence for the development of targeted treatment strategies based on the use of multikinase inhibitors in combination with mTOR inhibitors for the treatment of advanced prostate cancer.

KeywordsProstate cancer Castration-resistant prostate cancer PTEN Combination therapy Sorafenib Everolimus Mouse model Preclinical Electronic supplementary materialThe online version of this article doi:10.1186-s12967-015-0509-x contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Yutaka Yamamoto - Marco A De Velasco - Yurie Kura - Masahiro Nozawa - Yuji Hatanaka - Takashi Oki - Takayuki Ozeki - Nobut

Fuente: https://link.springer.com/

Documentos relacionados